Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.

Ciclesonide
Clinical data
Trade namesOmnaris, others
Other names(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.comMonograph
MedlinePlusa607008
Pregnancy
category
  • AU: B3
Routes of
administration
Nasal inhalation
ATC code
Legal status
Legal status
Identifiers
  • 2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.908 Edit this at Wikidata
Chemical and physical data
FormulaC32H44O7
Molar mass540.697 g·mol−1
3D model (JSmol)
  • O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C
  • InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 checkY
  • Key:LUKZNWIVRBCLON-GXOBDPJESA-N checkY
 ☒NcheckY (what is this?)  (verify)

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[6]

It was patented in 1990 and approved for medical use in 2005.[7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[8] It is on the World Health Organization's List of Essential Medicines.[9]

Society and culture

edit

Brand names

edit

It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.

References

edit
  1. ^ "Omnaris- ciclesonide spray". DailyMed. 8 November 2022. Retrieved 29 June 2024.
  2. ^ "Alvesco- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
  3. ^ "Zetonna- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
  4. ^ "Aservo Equihaler- ciclesonide spray, metered". DailyMed. 16 September 2021. Retrieved 29 June 2024.
  5. ^ "Aservo Equihaler EPAR". European Medicines Agency. 28 February 2020. Retrieved 29 June 2024.
  6. ^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
  7. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
  8. ^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 23 October 2006. Retrieved 30 July 2009.
  9. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

Further reading

edit
  • Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.